Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) CFO Richard P. Shea sold 971 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $13.67, for a total transaction of $13,273.57. Following the completion of the transaction, the chief financial officer now owns 131,731 shares of the company’s stock, valued at $1,800,762.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) traded up 0.74% during trading on Wednesday, reaching $13.65. 306,835 shares of the company were exchanged. The stock’s market capitalization is $941.26 million. The company’s 50-day moving average price is $12.20 and its 200-day moving average price is $11.63. Momenta Pharmaceuticals Inc. has a 1-year low of $7.86 and a 1-year high of $18.26.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The business earned $299.14 million during the quarter, compared to analysts’ expectations of $25.68 million. During the same period last year, the company posted ($0.44) EPS. The business’s revenue was up 2067.7% on a year-over-year basis. On average, equities analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.15) EPS for the current year.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Institutional investors have recently modified their holdings of the company. Pacad Investment Ltd. acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $103,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $109,000. Jane Street Group LLC acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $109,000. Profund Advisors LLC acquired a new position in shares of Momenta Pharmaceuticals during the third quarter worth approximately $121,000. Finally, Mason Street Advisors LLC acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $134,000. 81.62% of the stock is owned by institutional investors and hedge funds.

MNTA has been the subject of several recent research reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Thursday, October 13th. Brean Capital set a $19.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $18.00 price target on shares of Momenta Pharmaceuticals in a research note on Thursday, November 3rd. Barclays PLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Momenta Pharmaceuticals in a research note on Thursday, November 3rd. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Momenta Pharmaceuticals in a research note on Sunday, August 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. Momenta Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $16.10.

COPYRIGHT VIOLATION WARNING: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/11/23/richard-p-shea-sells-971-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

5 Day Chart for NASDAQ:MNTA

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.